Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV002472079 | SCV002768473 | uncertain significance | Spastic ataxia 4 | 2022-02-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as VUS-3B. Following criteria are met: 0102 - Loss of function has been reported to be a mechanism of disease in this gene in association with an MTPAP-related disorder (MIM#613672; PMID: 31779033). However, the gene-disease association is not clearly established. (I) 0106 - This gene has been reported to be associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from isoleucine to threonine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2; 2 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated fingers domain (PMID: 26319014). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0807 - This variant has no previous evidence of pathogenicity. This family, however, has been published in the literature (PMID: 31779033). (I) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Studies on fibroblasts from affected individuals from this family demonstrated reduced polyadenylation of mitochondrial transcripts and altered expression of mitochondrial proteins, relative to fibroblasts from a control (PMID: 31779033). (SP) 1205 - This variant has been shown to be maternally inherited (LABID). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |